Ultragenyx Pharmaceutical (RARE) Net Cash Flow Growth (3y) (2016 - 2026)
Ultragenyx Pharmaceutical (RARE) Net Cash Flow Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 89.97% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -13.44% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 33.37% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ultragenyx Pharmaceutical | 2.77 Bn | 2.36 Bn | 106.00 Mn | -74.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -74.51% |
| Dec 31, 2025 | 41.85% |
| Sep 30, 2025 | -52.12% |
| Jun 30, 2025 | 81.03% |
| Mar 31, 2025 | 33.12% |
| Dec 31, 2024 | -36.16% |
| Sep 30, 2024 | -52.81% |
| Jun 30, 2024 | 80.92% |
| Mar 31, 2024 | 33.60% |
| Dec 31, 2023 | -35.74% |
| Sep 30, 2023 | 41.08% |
| Jun 30, 2023 | -23.96% |
| Mar 31, 2023 | 29.95% |
| Dec 31, 2022 | -41.57% |
| Sep 30, 2022 | 211.81% |
| Jun 30, 2022 | 27.16% |
| Mar 31, 2022 | -43.88% |
| Dec 31, 2021 | 49.68% |
| Sep 30, 2021 | -49.25% |
| Jun 30, 2021 | 6.50% |